biotechnolog psychosi success stori initi buy pt
biotechnolog pubm pregam total tubular said surfer voic
 power forward power curv genco mtm weekli commentari
medic suppli devic chart week firepow
biotechnolog rlmd use right methadon treat depress initi coverag buy pt
declin dau modest concern news studi showsott churn higher pay tv
page analyst certif import disclosur
 psychosi success stori initi buy pt
publish decemb
messag thesi center around favor view nuplazid compani flagship product commerci potenti
parkinson diseas psychosi pdp dementia-rel psychosi drp drug track becom establish standard care pdp
believ approv launch nuplazid drp size pdp market like significantli increas commerci appeal
asset overal believ nuplazid could gener peak sale two indic beyond commerci potenti pdp
drp strong pipelin three pivot program underway nuplazid depress data like nuplazid schizophrenia
neg symptom trial begin data like trofinetid rett syndrom data possibl share
appreci significantli ytd vs btk trade market cap believ street impli nuplazid peak sale
assum peak revenu multipl believ conserv initi buy pt
rlmd use right methadon treat depress initi
coverag buy pt
publish decemb
messag relmada clinical-stag biotech focus develop therapi depress disord invest thesi relmada
center around posit view lead asset d-methadon current develop treatment resist depress trd major
depress disord mdd review phase ii data suggest treatment effect sever depress patient
rapid robust durabl drug shown rel benign safety/toler profil sound mechan compel phase
ii data optimist success plan phase trd program compani expect begin approv
could achiev peak sale trd upsid driven success indic rlmd share appreci
ytd vs btk trade ev fulli dilut view current valuat attract phase iii-readi asset multi-billion
dollar mood disord market expect share continu outperform clinic regulatori news flow initi buy pt
page analyst certif import disclosur
 ration return downgrad neutral
publish decemb
messag share impress move past month sinc bottom low august share seem get
credit stabil oper make progress outstand opioid litig share trade consensu
ebitda roughli premium peer feel comfort earn expect head believ
current valuat risk/reward share balanc lower rate neutral buy remov price
bhc buy hepat encephalopathi deep dive ahead phase
publish decemb
messag next decad believ find way acceler growth extend durabl xifaxan critic bhc largest
product sale total import pay debt could ultim help expand multipl bhc announc
sever new rifaximin studi includ phase studi acut ohe evalu formul interim analysi expect
sever nuanc make predict phase success challeng per kol call success think primari valu proposit acut
ohe label like come corollari expans xifaxan use prevent set
page analyst certif import disclosur
publish decemb
messag hznp teprotumumab ted receiv unanim adcom vote friday support risk-benefit profil drive share after-
hour trade particularli encourag adcom support broad label continu expect approv pdufa
date march given high unmet need orphan indic push toward pt believ compani well
posit drive success tepro launch next year bloomberg consensu tepro revenu addit possibl upsid driver
includ potenti krystexxa peak sale guidanc rais best idea
publish decemb
messag open letter mr diller typic fare sure probabl cost cut mayb
reinvest fuel growth might time consid someth bit radic target real issu loyalti low relianc
high advertis get harder offer two idea key underli theme data use buy inventori
rich barton-styl bhag brand oyo less controversi neither path would particularli easi either might help build
direct traffic critic margin
pubm pregam total tubular said surfer voic
publish decemb
messag rememb pneumat tube drive-through lane bank kind half crawl car window grab
cylindr plastic vessel load cash/check/deposit slip put vessel back tube zoom teller
window grab stuff process transact put receipt hope lollipop back vessel zoom
tube back car window basic except instead car bank gene-modifi macrophag pull
next diseas cell instead pneumat tube allow transport two cool littl thing call tunnel nanotub tnt
tube lot differ thing bodi case gene therapi turn provid direct mode transport healthi
cell diseas cell
page analyst certif import disclosur
forward power curv genco mtm weekli commentari
publish decemb
weekli market polici highlight takeaway page report
messag week week nation atc spark spread lower eastern market texa show loss nation
average region pjm nyiso show decreas follow ison ercot
atc power price lower across iso averag ny/ne/pjm show declin ercot lag
western market least lag natur ga price took anoth drop week henri hub price decreas
ny ne pjm declin ga price enough off-set power price power spark spread declin
continu neg impact ipp genco mark prior week ipp genco mark still higher vs end june
publish decemb
messag host cfo presid ndr new york boston manag emphas
custom experi becom essenti brand digit transform project well expand role data-driven ai/ml go
beyond autom improv qualiti interact believ well posit take advantag industri shift slew new
featur come potenti expand beyond much larger labor contact center
announc ceo stephan kasriel step end decemb hayden brown chief market product offic
elev top job rocki first year public compani believ chang guard seen posit investor
post better expect result revenu ep come ahead consensu digit media
exceed elev expect gener net new also bump exit run rate vs manag
indic marketo rebound experi platform saw good traction see softer subscript book last quarter cfo john murphi
reiter guid revenue ep
decemb veeva ndr lo angel
page analyst certif import disclosur
enter fray puct defer proceed
publish decemb
messag today puct open meet includ file potenti settlement electr intervenor result deferr
order januari turn event follow even construct statement puct chair time think
prior order would like see chang settlement prefer rout close proceed posit notion among
investor construct order today outcom better expect devil detail potenti settlement
read through well oncor
like limit impact consensu estim
publish decemb
messag collabor rog-sw morn announc phase studi evalu triplet regimen tecentriq
zelboraf cotel met primari endpoint progression-fre surviv braf-mut melanoma patient news increment posit
could potenti improv investor sentiment stock like impact street consensu estim given cotel low overal contribut
revenu competit market dynam within braf melanoma upcom result see preview repres
next potenti catalyst stock view kick data-fil maintain buy pt
 gosuranemab fail psp develop
discontinu psp tauopathi ad trial continu
publish decemb
messag anti-tau antibodi fail reach primari secondari endpoint phase ii passport studi progress
supranuclear palsi psp develop psp primari tauopathi termin though on-going phase ii tango
studi mild cognit ad impair continu news come surpris us follow failur anti
tau antibodi juli note believ result offer neg reinforc tau-deplet theori treat certain
neurodegen diseas key inflect point remain aducanumab potenti approv could come
page analyst certif import disclosur
golo approv
publish decemb
messag last night approv vyondi golodirsen line expect though came sooner anticip
approv put linger concern around srpt-specif neg sentiment fda moving/high bar dmd approv
rest therefor see posit read-through upcom casi file prospect approv spoke underscor
drug avail immedi still need work reimbursement/access hurdl lead sever mo delay pt like get drug
bottom line encourag though surpris quick execut reiter buy
publish decemb
messag overal ih global product forecast revis neg decemb global product forecast lower bp
mn unit y/i mn prior reduct europ na partial off-set increas china
forecast lower bp mn unit y/i modest increas na off-set declin china
sharp reduct europ continu downward revis european product forecast support view macro headwind
disrupt emiss regul neg impact vehicl demand region next year europ volum forecast still
ih na increas product volum expect like reflect better expect novemb us well pushout
believ ih assumpt around gm recoveri prove optimist ih expect lost volum recaptur
china volum expect modestli increas absent govern incent believ market modestli declin note ih
also expect market declin y/i
gm larg suv like featur fdm product
publish decemb
messag base recent press report appear full display mirror fdm product launch next gener gm full size
suv expect earli model assum unit new namepl product exist oem custom figur
look conserv announc namepl repres unit gm larg suv estim potenti
announc could contribut bp organ revenu growth vs bp estim prior
page analyst certif import disclosur
chart week firepow
publish decemb
messag med-tech activ slow sector pace announc fewest transact sinc total deal
valu set come second straight year vs acquir remain focus smaller tuck-in asset
case slowdown attribut compani still digest prior deal work intern issu think
gener healthi fundament across large-cap group still elev valuat publicli trade small-cap med-tech compani like
dampen activ well see assess potenti sector pick week cotw analyz balanc
sheet capac across mid-to-larg cap group
daili roll consolid viacomcb model buy rate declin dau modest concern
publish decemb
morri initi viacomcb buy rate price target see compani well posit broad reach signific
content product budget dtc opportun
cantwel view similarweb data fairli downbeat modest concern particularli context competitor expans
wong rais price target result better expect upsid digit media
gd gutman maintain buy rate follow manag meet week see consist demand increas deal size land bank
ensur pathway growth
publish decemb
page analyst certif import disclosur
guggenheim host client util event includ ndr
schedul scroll
integr resourc public comment continu pour
seri file joint motion adjust procedur schedul seri roe complaint
sharyland/oncor proceed transmiss line build necessari interconnect citi lubbock ercot hear oral argument
ferc/pjm pjm capac reform ad open meet docket next week
usfw aurelia skipwith confirm senat
seia residenti solar market reach record high
ny/solar nypsc releas order allow streamlin bill commun solar
spp wind reach new record peak spp
page analyst certif import disclosur
inc
page analyst certif import disclosur
primari analyst jake fuller
page analyst certif import disclosur
primari analyst glen santangelo
page analyst certif import disclosur
explor product
page analyst certif import disclosur
primari analyst michael schmidt
primari analyst etzer darout
life scienc tool omic
primari analyst david westenberg cfa
page analyst certif import disclosur
